WST logo

West Pharmaceutical Services, Inc. Stock Price

NYSE:WST Community·US$21.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 29 Fair Values set on narratives written by author

WST Share Price Performance

US$302.89
85.67 (39.44%)
US$349.85
Fair Value
US$302.89
85.67 (39.44%)
13.4% undervalued intrinsic discount
US$349.85
Fair Value
Price US$302.89
AnalystConsensusTarget US$349.85

WST Community Narratives

·
Fair Value US$349.85 13.4% undervalued intrinsic discount

Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
US$349.85
13.4% undervalued intrinsic discount
Revenue
6.07% p.a.
Profit Margin
19.56%
Future PE
39.07x
Price in 2029
US$437.25

Trending Discussion

Updated Narratives

WST logo

WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power

Fair Value: US$349.85 13.4% undervalued intrinsic discount
12 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
2 Rewards

West Pharmaceutical Services, Inc. Key Details

US$3.2b

Revenue

US$2.1b

Cost of Revenue

US$1.2b

Gross Profit

US$625.8m

Other Expenses

US$542.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
7.68
36.28%
16.85%
6.8%
View Full Analysis

About WST

Founded
1923
Employees
10800
CEO
Eric Green
WebsiteView website
www.westpharma.com

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Recent WST News & Updates

Seeking Alpha Apr 30

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking Alpha
Narrative Update Apr 27

WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power

Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.

Recent updates

No updates